30 C
Vientiane
Monday, June 9, 2025
spot_img
Home Blog Page 98

WeBank Technology Services Wins International Fintech Award

HONG KONG, May 26, 2025 /PRNewswire/ — On May 22, at the TAB Global Financial Technology Innovation Awards 2025 ceremony held by The Asian Banker (“TAB”), WeBank Technology Services and Fusion Bank were jointly awarded the Best Core Banking Technology Initiative (Small Bank) in Asia Pacific for their collaborated project of Next-Generation Core Banking System.

The TAB Global Financial Technology Innovation Awards is one of the most prestigious benchmarking awards for technology innovation leadership and performance in the global financial services industry. The Best Core Banking Technology Initiative specifically acknowledges institutions with exceptional technological advancement in core banking systems. This is the first time in three years that a Hong Kong digital bank won at the TAB Global Financial Technology Innovation Awards, indicating the technological leadership of the project’s collaborative achievement.

Fusion Bank and WeBank Technology Services were jointly awarded the Best Core Banking Technology Initiative (Small Bank) in Asia Pacific
Fusion Bank and WeBank Technology Services were jointly awarded the Best Core Banking Technology Initiative (Small Bank) in Asia Pacific

The award-winning project was launched to enhance Fusion Bank’s digital service capabilities and meet its business innovation and cost-efficiency needs to ensure the bank’s sustainable development. The project covered upgrade of over 150 subsystems across five core business areas of Fusion Bank, and was completed with a swift cutover in just 15 hours. The data in legacy systems from various vendors were seamlessly migrated to the new core banking system within merely six hours. Supported by WeBank Technology Services with its core banking system solutions, the project has set a new benchmark in banking system upgrade for the banking industry in Hong Kong.

Leveraging the distributed architecture design from WeBank Technology Services, the upgraded system can now scale on demand according to business growth, solving the previous pain points of high upfront IT investment. Additionally, it further enhances the business agility and shortens the time-to-market for new product launches, through parameterized products, process orchestration, and AI-native capabilities. After the new system went live, the product development cycle of Fusion Bank was reduced from an average of six months to three months, with non-human IT costs expected to be cut by 53% by 2027. Notably, the new system is widely compatible with mainstream software and hardware, offering the advantages of openness and being technology-agnostic.

The Asian Banker highlighted: “WeBank Technology Services and Fusion Bank have demonstrated exceptional innovation through the successful execution of this technology initiative, effectively addressing current and future business needs while enhancing service capabilities. This has resulted in notable business outcomes, significant efficiency gains and enhanced customer value, surpassing industry peers.”

Billy Chiu, Chief Technology Officer of Fusion Bank, said: “We are truly honored to be the only Hong Kong digital bank receiving this award in the past three years. It is a significant recognition for both Fusion Bank and WeBank Technology Services. The upgrade of our next-generation core banking system shows our ongoing commitment to advancing financial inclusion through fintech, making our banking services more accessible and efficient for a broader segment of the community.”

As the wholly-owned fintech arm of WeBank, WeBank Technology Services leverages the parent company’s leading practices in digital banking, focuses on providing digital finance and digital infrastructure solutions globally. Currently, WeBank Technology Services is expanding its partnership with multiple institutions across markets like Hong Kong SAR, Indonesia, Thailand, Malaysia and Qatar.

About WeBank Technology Services

Launched in Hong Kong in June 2024, WeBank Technology Services sets out to leverage WeBank’s cutting-edge fintech capabilities and digital finance best practice to deliver a variety of superior digital finance and digital infrastructure solutions to digital banks, financial institutions, government agencies, and industry partners worldwide.

About WeBank

Established in 2014, WeBank Co., Ltd. (“WeBank”) is the first digital bank in China. WeBank provides convenient financial services to micro-, small- and medium-sized enterprises (MSMEs) and the public, and continuously improves the quality of services in response to customers’ specific needs. WeBank has served over 420 million retail customers and 5.8 million enterprises.

WeBank has pioneered the development of the world’s first fully distributed next-generation core banking system using standardized hardware and open-source software. It maintains an exceptional system availability of 99.999% with peak daily transaction exceeding 1.4 billion, while the annual IT O&M cost per account remains as low as USD 0.3, only one-tenth of the industry average.

CNOOC Limited Announces Mero4 Project Commences Production

HONG KONG, May 26, 2025 /PRNewswire/ — CNOOC Limited (the “Company”, SEHK: 00883 (HKD Counter) and 80883 (RMB Counter), SSE: 600938) announces that Mero4 Project has commenced production safely at May 24 Brazil time.

Mero field is located in the Santos Basin pre-salt southeastern offshore Brazil, about 180 kilometers away from Rio de Janeiro, in a water depth of between 1,800 and 2,100 meters. Mero4 Project will be developed by the traditional deep-water Pre-salt development mode, FPSO+Subsea. 12 development wells are planned to be commissioned, including 5 oil producers, 6 water or gas alternate injectors, 1 convertible well. In order to maximize production, the wells are equipped with intelligent well completion technology, which enables the remotely switching between production and injection wells via platform.

The FPSO used in Mero4 is one of the largest FPSOs in the world, which was integrated in China in December 2024 and arrived at the oilfield in March 2025. The FPSO is able to produce up to 180,000 barrels of crude oil, process 12 million cubic meters of natural gas per day and inject 250,000 cubic meters of water, which will increase the installed production capacity of Mero field to 770,000 barrels of crude oil per day.

To implement the concept of green and low carbon development, Mero4 project is also equipped with resources to operate the HISEP (High Pressure Separator), which allows underwater separation between the extracted oil and the associated gas and reinject the gas into the reservoir. The HISEP will simultaneously boost production and reduce emission.

CNOOC Petroleum Brasil Ltda, a wholly-owned subsidiary of CNOOC Limited, holds 9.65% interest. Petrobras is the operator and has 38.6% interest, TotalEnergies holds 19.3% interest, Shell Brasil holds 19.3% interest, CNPC holds 9.65% interest, and Pré-Sal Petróleo S.A –PPSA holds 3.5% as the Federal Union representative in non-contracted areas.

— End —

Notes to Editors:

More information about the Company is available at http://www.cnoocltd.com.

*** *** *** ***

This press release includes forward looking information, including statements regarding the likely future developments in the business of the Company and its subsidiaries, such as expected future events, business prospects or financial results. The words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify such forward-looking statements. These statements are based on assumptions and analyses made by the Company as of this date in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company currently believes are appropriate under the circumstances. However, whether actual results and developments will meet the current expectations and predictions of the Company is uncertain. Actual results, performance and financial condition may differ materially from the Company’s expectations, including but not limited to those associated with macro-political and economic factors, fluctuations in crude oil and natural gas prices, the highly competitive nature of the oil and natural gas industry, climate change and environmental policies, the Company’s price forecast, mergers, acquisitions and divestments activities, HSSE and insurance policies and changes in anti-corruption, anti-fraud, anti-money laundering and corporate governance laws and regulations.

Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements. The Company cannot assure that the results or developments anticipated will be realised or, even if substantially realised, that they will have the expected effect on the Company, its business or operations.

*** *** *** ***

For further enquiries, please contact:

Ms. Cui Liu
Media & Public Relations
CNOOC Limited
Tel: +86-10-8452-6641
Fax: +86-10-8452-1441
E-mail: mr@cnooc.com.cn 

Mr. Cheng Yao
Ever Bloom (HK) Communications Consultants Group Limited
Tel:+852 5540 0725
Fax:+852 2111 1103
Email:cnooc.hk.list@everbloom.com.cn 

 

UGREEN Partners with Best Buy, Significantly Expanding Retail Presence Across the United States

UGREEN’s innovative electronic devices and accessories now available on BestBuy.com and in hundreds of Best Buy retail stores nationwide.

WILMINGTON, Del., May 26, 2025 /PRNewswire/ — UGREEN, a global innovator in consumer electronics, today announced that Best Buy, the world’s largest specialty consumer electronics retailer, now offers UGREEN’s sought-after products to Best Buy customers via BestBuy.com and hundreds of Best Buy brick-and-mortar locations across the United States.

Since its founding, UGREEN has focused on delivering technologically advanced products that meet the evolving needs of consumers. This partnership with Best Buy is a major strategic initiative for UGREEN and marks a significant step in its continued North American expansion, and aligns perfectly with a core mission to make high-quality, user-focused technology more accessible. By partnering with a trusted retail leader like Best Buy, UGREEN will serve an even broader audience seeking reliable and innovative electronic solutions to improve their lives.

“We are thrilled to be working with Best Buy, a household name synonymous with consumer electronics in the United States,” said Nancy Yu, the Overseas Sales Director of UGREEN. “This collaboration allows us to connect with a vast new customer base and offer them our cutting-edge charging solutions and accessories directly through Best Buy’s extensive digital and physical retail network and leverage their ability to help customers choose the best options to fit their unique needs. It’s a significant step forward in our mission to provide value and innovation to consumers across North America.” 

A curated selection of UGREEN’s popular mobile accessory products will be available to Best Buy customers, including:

About UGREEN

Since 2012, UGREEN has been dedicated to creating innovative electronic devices and accessories that are both technologically advanced and affordable for consumers. Its user-focused approach lies at the core of the brand, which has earned the trust of over 200 million users globally.

About Best Buy

Best Buy (NYSE: BBY) is the world’s largest specialty consumer electronics retailer. Best Buy’s purpose is to enrich lives through technology, which Best Buy do by providing their customers a unique mix of advice, products and services in our stores, online, and in homes. More information can be found at https://www.bestbuy.com/

Contact: pr@ugreen.com

 

MGI Tech Showcases Comprehensive Multi-Omics Solutions at ESHG 2025 Milan

MILAN, May 26, 2025 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, unveiled cutting-edge multi-omics technologies at the European Society of Human Genetics (ESHG) 2025 conference in Milan. At Booth #310, MGI highlighted its advanced sequencing and automation platforms, including the new mid-throughput sequencer DNBSEQ-T1+ and the single-cell library preparation workstation DNBelab C-YellowR 16, designed to enhance precision and efficiency in omics research.

Innovation Highlights in Sequencing and Single-Cell Automation

MGI introduced the DNBelab C-YellowR 16, making its global debut, which enables the parallel processing of up to 16 single-cell samples, reducing hands-on time by up to 90% while maintaining high reproducibility and precision. 

DNBelab C-YellowR 16 offers a seamless transition from cell and nucleus suspension input to the output of DNA nanoballs (DNBs) ready for sequencing.

With multiple integrated functional modules, it delivers a fully automated workflow without user intervention. The integrated 8-channel independent pipetting module handles plate transfer and pipetting across the entire process. Its  Single-cell Droplet Generation module performs cell sorting and labeling, while the PCR instrument, Magnetic Bead Purification Module, and Shaker modules facilitate high-throughput library preparation. A built-in DNA Concentration Detection module ensures rigorous library quality control (QC).

YellowR 16 achieves a truly unattended workflow – from cell sorting to library preparation, and library QC – enabling hands-free operation with stability and reliability. This groundbreaking solution addresses the limitations of manual single-cell operations, such as operational complexity, low throughput, and data variability.

To further enhance its offering for transcriptome applications, based on Xpress Genomics technology, MGI has developed a highly sensitive full-length transcriptome library preparation solution. This enables full-length transcriptome profiling from as little as 10 pg of RNA or low to 10 cells, making it ideal for challenging or limited-input research scenarios.

“We are thrilled to present our latest innovations at ESHG, a pivotal gathering for Europe’s genomics community,” said Dr. Christian Zimmerman, VP of Sales, Europe & Africa at MGI. “We’re invigorated by the remarkable momentum propelling integrated multi-omics workflows! Our pioneering platforms, notably Stereo-seq and the DNBelab C-YellowR 16, unveiled for the first time at ESHG, are generating profound enthusiasm. The resounding acclaim for our robust sequencing technology and sophisticated automation is deeply resonant, forging strong connections with researchers and clinical laboratories throughout Europe.”

The platform’s streamlined, all-in-one design makes it ideal for labs seeking scalable, walkaway automation in single-cell genomics. A vibrant live demonstration at the booth captivated researchers, igniting excitement for novel strategies to optimize workflow efficiency.

During the ESHG exhibition, MGI also presented its versatile sequencing portfolio, ranging from benchtop to ultra-high-throughput platforms – including the DNBSEQ-T1+, first introduced at AGBT 2025. Positioned between compact and large-scale systems, the T1+ offers flexible mid-throughput sequencing for both clinical and research environments.

Corporate Satellite Symposium: Real-World Genomic Applications

On May 24, MGI hosted a Corporate Satellite Symposium, featuring global experts discussing practical applications of the DNBSEQ™ platform.

Prof. Jānis Kloviņš, Professor and Head of the Scientific Council at the Latvian Biomedical Research and Study Centre, presented his team’s work on building a national genomic infrastructure as part of the European 1+ Million Genomes Initiative. Using DNBSEQ-T7 for whole-genome sequencing, his team is developing a high-resolution Latvian population reference, supporting both rare disease diagnostics and polygenic risk scoring.

“MGI’s sequencing platform has allowed us to build a national genomic infrastructure at scale and also perform diagnostic and prognostic tests,” said Prof. Kloviņš. “We see great promise in integrating these technologies across clinical and population health systems.”

Dr. Eirini Papadopoulou, International Laboratory Director at Genekor Medical S.A. in Greece, highlighted the transformative role of NGS-based multigene panels in precision oncology, enabling the identification of predictive and prognostic biomarkers to drive highly personalized treatment strategies. Meanwhile, Dr. Xin Jin, Chief Scientist and Director at the Institute of Precision Health Research, BGI-Research, presented roundbreaking results from the China Kadoorie Biobank, where MGI’s platforms sequenced over 500,000 genomes in just six months. His presentation demonstrated the power and scalability of MGI’s platforms and omics capabilities for delivering population-wide insights with global health impact.

Driving European Genomics Forward

MGI’s steadfast dedication to Europe’s genomics landscape is evident through its pivotal contributions to landmark initiatives like the European ‘1+ Million Genomes’ Initiative and the Kadoorie Biobank, underscoring its role in advancing both population genomics and clinical research.

Europe continues to be a strategic focus for MGI” said Dr. Yong Hou, General Manager, Europe & Africa at MGI, ” From national population programs to clinical labs, we’re proud to support projects that are reshaping personalized medicine and making genomics more accessible across the region. This year also marks the 10th anniversary of our DNBSEQ™ technology – now trusted in over 100 countries worldwide – and we’re excited to see it driving innovation across Europe and Africa“.

 

Neutech Group strategically expands wellness tourism business resources, accelerating the development of new ecosystem of education, healthcare, wellness and mind tour

HONG KONG, May 26, 2025 /PRNewswire/ — On 20 May 2025, Neutech Group Limited (“Neutech Group” or the “Group”; stock code: 9616.HK) announced the acquisition of partial equity interest in Xikang Wellness & Resorts, which will further strengthen the Group’s integration of resources in the “wellness tourism” business, support the specialized development of elderly education, and expand the practical education platform for universities. This acquisition marks a crucial step in the Group’s strategy layout of “education-healthcare-wellness and mind tour”, fully demonstrating the Group’s strategic resolve to advance the integrated development of the five business ecosystems.

Since 2024, leveraging its longstanding advantages and extensive experience in the “education + technology + medical care”, Neutech Group has been driving continuous technological innovation to build a new vision for the integrated development of “education-healthcare-wellness and mind tour”. In the field of full-time higher education, relying on its strong industrial background and technological resource advantages, the Group has established three IT application-oriented undergraduate universities in Dalian, Chengdu and Foshan, cultivating over 170,000 IT applied talents for society. In the field of educational resource services, the Group empowers more than 700 universities and vocational colleges across China with first-class educational products and services. In the field of medical and health care, the Group actively expands medical and health care services by leveraging high-end medical rehabilitation resources, including its subsidiaries cardiovascular hospital, stomatology hospital and Wecare Family Nursing Home, as well as the upcoming Ruikang Rehabilitation Hospital. In the field of lifelong education and health technology, the Group closely addresses the personalized needs of seniors in learning, social engagement, and health. The Group established the Neuedu Phoenix Academy senior education brand and built a distinctive whole-lifecycle elderly health service system, while integrating its new practice of integrated development in “education-healthcare-wellness and mind tour” with Neutech’s city-level smart elderly care platform, and creating a new smart eldercare ecosystem that combines online and offline services by integrating the needs of home-based, community-based, and institutional elderly care.

Through equity investment in Xikang Wellness & Resorts, the Group will harness the power of its nationwide network of hotels to deepen collaboration and synergy between Xikang Wellness & Resorts and elderly education business, which will promote mutual benefits and win-win outcomes for both parties, integrating wellness tourism, senior study tours, and educational practices to establish a comprehensive elderly education model of “learning-travel-care”. In addition, Xikang Wellness & Resorts also serves as a joint practice base for the Group’s three universities, effectively establishing an industry-academia-research collaborative innovation platform, further promoting the deep integration of educational chains, talent chains, and industrial chains.

Looking ahead, Neutech Group Limited will advance the implementation of integrated strategy of “education-healthcare-wellness and mind tour”. With education serving as the core, foundation, and nexus, the Group will not only enhance the high-quality development of education technology business but also further refine healthcare and wellness service system, creating a virtuous cycle where education enables empowerment, healthcare provides support, wellness services improve quality, and residential tourism adds value. Pioneering a new paradigm of integrated development of “education-healthcare-wellness and mind tour”, the Group empowers the education-healthcare-wellness ecosystem through technological innovation, and innovates digital and intelligent lifestyles through education, aiming to become the pioneer in building an ecosystem of education, healthcare, wellness and mind tour.

About Neutech Group Limited

Neutech Group Limited (referred to as “Neutech Group” or “the Group”), since its establishment in 2000, has developed over twenty-five years to become a leading provider of digital talent education services and a pioneer of teaching, medical, health care and tourism ecology. In response to China’s accelerating aging population, the Group strategically expanded into elderly education and healthcare services starting in 2024. Relying on the innovative research and development capability of “education + technology + medical care” the Group is creating a new integrated model of “teaching, medical care, health and tourism.” Currently, the Group operates two main business sectors: (i) Education Services; and (ii) Medical and Healthcare Service. The education service encompasses three key categories:(i) Full-time higher education services; (ii) Educational resource empowerment; and (iii) Lifelong education services. The medical and healthcare service comprises two principal domains:(i) Medical services; and (ii) healthcare services.

CONTACT: Lin Wei, weilin@neuedu.com

Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025

  • DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2%
  • DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and durable anti-tumor activity with favorable safety and tolerability as a monotherapy in heavily pre-treated non-small cell lung cancer (NSCLC) patients with EGFR-mutations

SHANGHAI, May 26, 2025 /PRNewswire/ — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that it will present latest clinical study results of its investigational drugs DZD8586 and DZD6008 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The studies focus on B-cell non-Hodgkin lymphomas (B-NHLs) and non-small cell lung cancer (NSCLC) two disease areas Dizal has approved drugs and strong clinical pipeline.

DZD8586: A Potential Novel Therapeutic Option for Patients with B-NHL

A pooled analysis of two phase I/II studies of DZD8586 in CLL/SLL patients after treatment with covalent or non-covalent BTK inhibitors and BTK degraders (Abstract #7010) was selected for an oral presentation:

  • An objective response rate (ORR) of 84.2% was achieved. Tumor response was observed in patients previously treated with BTK inhibitors and BCL-2 inhibitors, with response rates of 82.4% and 83.3%, respectively.
  • Tumor response was observed irrespective of prior covalent/non-covalent BTK inhibitor, BTK degrader, or BCL-2 inhibitor treatment, and in patients with classic BTK resistance mutations (C481X) as well as other BTK mutations, including kinase-dead mutations.
  • Response was durable, with an estimated 9-month duration of response (DOR) rate of 83.3%.

Prof. Jianyong Li, MD, PhD at Jiangsu Province Hospital, and the leading principal investigator of the study, said,DZD8586 has shown promising antitumor activity in patients with relapsed/refractory CLL/SLL. By targeting both BTK-dependent and -independent signaling pathways, it could overcome resistance driven by target depletion or bypass activation, addressing significant limitations of current BTK inhibitors. We look forward to continued data readout from ongoing clinical studies.”

In addition, a Phase II study of DZD8586 as monotherapy in relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) (Abstract # e19050) will also be presented at the conference. Patients recruited in the trial had received 1-4 prior lines of therapy, and all were treated with anthracycline-and CD20-antibody based chemoimmunotherapy. At the doses of 50 mg and 75 mg QD, DZD8586 demonstrated promising antitumor activity and a manageable safety profile. Tumor responses were observed in both germinal center B-cell-like (GCB) and non-GCB subtypes. Updated results from this study will be disclosed at the 2025 European Hematology Association (EHA) Annual Congress.

Prof. Lugui Qiu, MD, PhD at Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, the leading principal investigator of this study, said, “Treatment resistance in relapsed/refractory DLBCL remains a major clinical challenge. DZD8586, a non-covalent dual LYN/BTK inhibitor, has shown activity in both GCB and non-GCG subtypes, an important feature. With full BBB penetration and a favorable safety profile, it also shows promise in patients with CNS involvement, who typically confront a poor prognosis.”

DZD6008: A 4th generation EGFR TKI Poised to Address Unmet Needs in NSCLC

The presentation at ASCO 2025 will feature promising pre-clinical and early clinical data from an ongoing Phase I/II TIAN-SHAN2 study of DZD6008 in patients with EGFRm NSCLC (Abstract #8616). Preclinical studies showed that DZD6008 was potent against EGFR mutations, including single (L858R/19del), double (T790M and L858R/19del), and triple mutations (C797X, T790M and 19del), with good selectivity (> 50-fold) over wild-type EGFR.

As of March 31, 2025, a total of 12 EGFRm NSCLC patients were enrolled in the study during the dose escalation phase. The median number of prior lines of therapy was 4.5 (range 2-8). DZD6008 monotherapy demonstrated encouraging and durable antitumor activity with good tolerability in this heavily pre-treated population. Ten patients (83.3%) showed target lesion shrinkage with DZD6008 treatment. Partial response (PR) was observed at ≥20 mg. In line with preclinical findings, DZD6008 exhibited excellent BBB penetration, as well as sustained efficacy in patients with brain metastases. The ratio of measured free drug concentrations in CSF over plasma is over 1.0.

Prof. Mengzhao Wang, MD, PhD at Peking Union Medical College Hospital, the leading principal investigator of the study said,DZD6008 is a novel, highly selective, full-BBB penetrant EGFR TKI with broad-spectrum of activity against different EGFR mutations. The clinical data revealed at ASCO 2025 suggested that DZD6008 has good antitumor activity and tolerability in EGFRm NSCLC patients who were resistant to EGFR TKIs, especially their durable remission effect on metastatic brain lesions. The ongoing TIAN-SHAN2 study aims to further validate these findings in a broader patient population.”

“The clinical data on DZD8586 and DZD6008 presented at this year’s ASCO further highlight our strong R&D capabilities and competitive edge in tackling difficult-to-treat hematologic malignancies and lung cancer. The significant efficacy data and encouraging safety profile give us confidence to push forward to accelerate its clinical development programs,” said Xiaolin Zhang, PhD, CEO of Dizal.

About DZD8586
DZD8586 is a first-in-class, non-covalent, LYN/BTK dual inhibitor with full blood-brain barrier (BBB) penetration, designed as a potential treatment option for B-cell non-Hodgkin lymphoma (B-NHL).

While Bruton’s Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can arise through two major mechanisms: the BTK C481X mutation and BTK-independent BCR signaling pathway activation. Currently, there is no targeted therapy available to address both resistance mechanisms, posing an urgent clinical challenge. Although BTK degraders have shown encouraging efficacy in early clinical studies, mutation-related resistance has been reported, and degrader-related toxicities may affect long-term clinical application.

DZD8586 has high selectivity against other TEC family kinases (TEC, ITK, TXK and BMX). By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. Phase I clinical trial suggests that DZD8586 exhibits favorable PK properties, good central nervous system (CNS) permeability, complete blockade of BCR signaling, and encouraging anti-tumor efficacy with good safety and tolerability in patients with B-NHL.

About DZD6008
DZD6008 is a novel, highly selective, full-BBB penetrant EGFR TKI, designed as a potential treatment option for advanced EGFR mutation positive (EGFRm) NSCLC.

Non-small cell lung cancer is the leading cause of cancer death in the world. Epidermal growth factor receptor (EGFR) gene is one of the most common driver genes for NSCLC. Multiple agents can be used to treat patients with EGFR mutated NSCLC who develop resistance to EGFR tyrosine kinase inhibitors (TKIs), but the clinical outcome was not satisfactory. Brain metastases (BM) are a leading cause of death and disease progression for NSCLC. Approximately 23%-30% of NSCLC patients are synchronous BM at their initial diagnosis. Previous studies reported that the 3-year cumulative rate of BMs ranges from 29.4% to 60.3% in patients with mutated EGFR.

Currently, the clinical benefits of existing treatments for third-generation EGFR TKI-resistant NSCLC are limited and DZD6008 is expected to fill the unmet medical needs. DZD6008 effectively inhibits EGFR-mutated tumor growth in cell lines and in animal models. Previous clinical studies have validated the design concept of the molecule and suggest that DZD6008 demonstrates good safety and efficacy in NSCLC patients with brain metastases who had failed third-generation EGFR TKI therapy or multiple lines of pre-treatments.

About Dizal
Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deeply rooted in translational science and molecular design, it has established an internationally competitive portfolio with two leading assets in global pivotal studies, both of which have already been launched in China.

To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or X.

Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, and “intend” and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts
Investor Relations: ir@dizalpharma.com
Business Development: bd@dizalpharma.com
Media Contact: pr@dizalpharma.com

Esaote: The new MyLab™Heron ultrasound scanner for veterinary physicians had its world premiere at the SCIVAC Rimini 2025 Congress

GENOA, Italy, May 26, 2025 /PRNewswire/ — Esaote, a leading company in the field of medical diagnostic imaging, has presented the world premiere of the new MyLab™Heron ultrasound system at the Congress organized in Rimini from May 23 to 25 May by SCIVAC, the largest Veterinary Scientific Society in Italy, the objective of which is the scientific and professional education of veterinarians.

The new MyLab™Heron ultrasound scanner
The new MyLab™Heron ultrasound scanner

MyLab™Heron is the latest result of Esaote’s research activity in high-performance portable ultrasound systems, in which the Company has now been recognized for over 30 years and where it stands out for its comprehensive product portfolio and innovative solutions. 

“Veterinary physicians,” stated Erminio Bassi, Esaote Vet Business Manager, “are always looking for tools that improve accuracy and efficiency, and this new ultrasound system meets these needs perfectly.”

MyLab™Heron is inspired by the animal from which it takes its characteristics of precision and ease of movement, even in challenging conditions, and is a portable system that combines superior performance, ease of use and mobility, including a fully cleanable touch interface. Access to all functions, from simple to advanced, is simple, intuitive and customizable, while its compact size and long-lasting battery make it ideal in any clinical setting.

Workflows are designed to reduce the number of actions and to enable the veterinarian to focus on caring for the animal. Advanced technology and dedicated veterinary solutions make the diagnostic process simple and reliable. The result is faster and more accurate decisions. By analyzing real-time imaging data, artificial intelligence features built into the system reduce operator input, improving overall workflow and productivity.

Similarly, MyLab™Heron offers high-resolution imaging in both superficial and deeper areas, thanks to the wide range of probes available. All this makes it possible to scan animals of any size in all applications, from general imaging to cardiology, from the musculoskeletal system to reproduction, providing unparalleled clarity. A powerful tool designed to support veterinarians working in clinics, hospitals and independently.

MyLab™Heron supplements and enriches the range of Esaote ultrasound scanners dedicated to veterinary medicine, of which MyLab™Fox and MyLab™Panther are well-established, widely recognized benchmarks in international markets. They demonstrate the attention to innovation and detail with which Esaote intends to make veterinary care increasingly accessible and decisive, to improve proximity to animals and the people who love them.

Esaote also supports veterinary physicians in diagnostic imaging with training programs and education, from webinars to live events; it is convinced that its vision of care based on sharing, research, and discussion with experts can help improve the future of veterinary medicine and enhance the role of the animal doctor.

Esaote Group Leader in medical imaging (ultrasound, MRI, software to manage the diagnostic process). At the end of 2024, the Group had approximately 1,300 employees, half of whom in Italy. With facilities in Genoa and Florence, and its own production and research units in Italy and the Netherlands, Esaote maintains a presence in over 100 countries around the world. www.esaotevet.com.

© Copyright Esaote 2025

 

Vibracoustic Selects DXC to Lead Global Business Transformation with SAP

ASHBURN, Va., May 26, 2025 /PRNewswire/ — DXC Technology (NYSE: DXC), a leading Fortune 500 global technology services provider, today announced a multi-year IT services agreement with Vibracoustic, a leading expert in automotive Noise, Vibration, and Harshness (NVH) solutions to transform its SAP environment and modernize global IT operations.

Vibracoustic Selects DXC to Lead Global Business Transformation with SAP
Vibracoustic Selects DXC to Lead Global Business Transformation with SAP

Under the five-year agreement, DXC will become Vibracoustic’s strategic partner for SAP services, taking responsibility for the company’s global SAP Application Development and Management Services (ADMS) across 17 countries and over 30 manufacturing facilities. The transformation will streamline operations, standardize processes, and improve service delivery for more than 5,000 users.

“DXC’s unparalleled expertise in SAP solutions, its ability to manage complex global IT systems, and client-centric approach make it the ideal partner,” said Nico Klohr, Commodity IT Manager at Vibracoustic. “With DXC’s support, we are confident in achieving a unified and efficient SAP service landscape that will further enhance productivity and drive growth.”

By consolidating multiple existing vendors into a single, integrated global service led by DXC, Vibracoustic aims to reduce complexity, enhance consistency, and accelerate innovation.

“With over 15,000 SAP professionals worldwide and over 5 million SAP users supported globally, DXC is a leading provider of SAP solutions, helping businesses to quickly respond to market dynamics, simplify operations, and minimize the disruption, risks and costs of enterprise transformation,” said Juan Parra, President, DXC Europe. “As Vibracoustic’s global strategic supplier, we will manage its mission-critical SAP systems and help to drive greater efficiency across the organization.”

This agreement underscores DXC’s position as a leader in major IT transformations, reaffirmed by its recent recognition in PAC’s SAP Services Europe report as well as Whitelane Research’s 2024/2025 European IT Sourcing Study.

DXC has over 35 years of experience delivering SAP solutions, with a global team of 15,000+ SAP professionals and 2,500+ SAP certifications. DXC supports nearly 850 SAP customers across 60 countries, helping customers simplify operations, scale efficiently, and drive innovation through end-to-end SAP transformation strategies. To learn more, visit DXC.com

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission-critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. The world’s largest companies and public sector organizations trust DXC to deploy services to drive new levels of performance, competitiveness, and customer experience across their IT estates. Learn more about how we deliver excellence for our customers and colleagues at DXC.com.

About Vibracoustic

Vibracoustic is a leading global automotive NVH expert, providing customized solutions adding comfort and supporting efficiency, safety and durability. Its expertise along the entire product life cycle and all vehicle systems as well as its broad product range enable Vibracoustic to solve current and future NVH challenges across all automotive segments. With approximately 12,000 employees at around 40 production and engineering locations across 17 countries, Vibracoustic serves all major automotive manufacturers. In 2024 Vibracoustic recorded total sales of 2.6 billion €. For more information, see www.vibracoustic.com

Forward Looking Statements

All statements in this press release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” These statements represent current expectations and beliefs, and no assurance can be given that any result, goal or plan set forth in any forward-looking statement can or will be achieved. Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. For a written description of these factors, see the section titled “Risk Factors” in DXC’s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, and any updating information in subsequent SEC filings. Readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, except as required by law.

Contact: Angelena Abate | +1 646 234 8060 | angelena.abate@dxc.com